Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00280098

Enrollment

Registered

2006-01-20

Start date

2006-01-31

Completion date

Unknown

Last updated

2009-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Neoplasms

Brief summary

Evaluation of safety and efficacy of docetaxel in the treatment of advanced hormone refractory prostate cancer under the conditions of daily practise.

Interventions

DRUGdocetaxel

Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional. Main criteria are listed hereafter : Inclusion Criteria: * Patients with advanced prostate cancer, without previous chemotherapy, progressing on hormonal treatment, performance status 1 to 2

Exclusion criteria

* Other cytostatic treatment, other malignity, severe comorbidity

Design outcomes

Primary

Measure	Time frame
PSA decline	after each docetaxel administration and after the end of treatment
pain response	after each docetaxel administration and after the end of treatment
side effects occurrence	Throughout the study

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026